Stay updated on FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial

Sign up to get notified when there's something new on the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:41:10.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies for subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia.
    Difference
    0.1%
    Check dated 2024-06-06T14:43:21.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the required diagnosis of B-cell lymphoma or CLL, and listing key inclusion and exclusion criteria for the study.
    Difference
    22%
    Check dated 2024-05-22T21:34:30.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:28:50.000Z thumbnail image

Stay in the know with updates to FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page.